Bydevin Mclaughlin News Today

CHICAGO — Mirvetuximab soravtansine-gynx extended survival of women with platinum-resistant ovarian cancer and high folate receptor-alpha expression, according to a study that compared the agent with investigator’s choice of chemotherapy.The antibody and microtubule inhibitor conjugate is the first novel therapy to show a survival benefit in a randomized phase 3 study among this

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.The HER2-directed antibody-drug conjugate, also known as T-DXd (Enhertu; AstraZeneca, Daiichi Sankyo), demonstrated the highest objective response rates and most durable

CHICAGO — Ivosidenib extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial.The long-term follow-up data, presented at ASCO Annual Meeting, showed an additional 5-month increase in median OS with the ivosidenib (Tibsovo, Servier)

CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.The findings appeared consistent with those of studies that explored a combination of neoadjuvant chemotherapy and dual HER2-targeted treatments, with no

CHICAGO — Assessment of RUBY trial outcomes by blinded independent central review confirmed the benefits of adding dostarlimab to chemotherapy for women with primary advanced or recurrent endometrial cancer.The findings, presented at ASCO Annual Meeting, showed clinically meaningful PFS improvement with the dostarlimab (Jemperli, GSK) regimen vs. chemotherapy alone among women with mismatch

CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.“The most important point of PRODIGE 23 is the overall survival benefit,” Thierry Conroy, MD, of the department of medical oncology at Institut de

CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer, according to study results presented at ASCO Annual Meeting.“Neoadjuvant FOLFIRINOX showed acceptable safety and resectability rates,” Knut Jørgen Labori, MD, PhD, of the department of hepato-pancreato-biliary surgery at Oslo

CHICAGO — Fewer than half of adolescents and young adults with acute lymphoblastic leukemia received first-line treatment at a specialized cancer center, despite an association of such treatment with longer survival, study results showed.The findings, presented at ASCO Annual Meeting, also revealed independent associations of age, race/ethnicity and insurance type with odds of treatment at

The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.The findings of the randomized, phase 3 EMBARK study, presented during American Urological Association Annual Meeting, also showed a statistically significant and clinically

A combination of toripalimab and perioperative chemotherapy significantly extended EFS compared with chemotherapy alone among patients with resectable stage III non-small cell lung cancer, according to results of a randomized phase 3 study.The findings of the Neotorch study, presented during an ASCO Plenary Series session, also showed the addition of toripalimab (Junshi Biosciences) to